Samalin Investment Counsel’s Biogen BIIB Stock Holding History

Samalin Investment Counsel’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-132	Closed	-$39K	–	180
2019 Q4	$39K	Buy	+132	New	+$36.6K	0.03%	307

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Samalin Investment Counsel's BIIB Position: Q1 2020 in Review

Samalin Investment Counsel sold out of Biogen (BIIB) in Q1 2020, closing a stake of 132 shares — an estimated $39K sold.

Samalin Investment Counsel first reported a position in BIIB in Q4 2019 and held it in 1 quarter. The position peaked at $39K in Q4 2019. 1,098 funds tracked by Wall St. Rank hold BIIB as of Q1 2020.

Samalin Investment Counsel reported no remaining Biogen position as of Q1 2020 after selling out during the quarter.
Samalin Investment Counsel sold 132 Biogen shares in Q1 2020, an estimated $39K.
Samalin Investment Counsel first reported a position in Biogen in Q4 2019 and held it in 1 quarter.
Samalin Investment Counsel's Biogen position peaked at $39K in Q4 2019.
1,098 funds tracked by Wall St. Rank held Biogen as of Q1 2020.

Based on Samalin Investment Counsel's 13F filing for Q1 2020, filed 4 May 2020.